GSK2485852 + ritonavir

GSK2485852 + ritonavir is an investigational combination therapy developed for the treatment of chronic hepatitis C virus (HCV) infection. GSK2485852 is a non-nucleoside inhibitor targeting the NS5B polymerase at site IV of the HCV replication complex, thereby inhibiting viral RNA synthesis[2]. Ritonavir is a protease inhibitor primarily used as a pharmacokinetic booster; it inhibits cytochrome P450 3A4 (CYP3A4), increasing plasma concentrations and prolonging the activity of co-administered drugs[5][6]. In this combination, ritonavir serves to enhance exposure to GSK2485852 by reducing its metabolic clearance. The development status for this combination in HCV was terminated after early-phase clinical trials[3].